Rexahn Pharmaceuticals Announces the Appointment of Peter Brandt and Richard Kivel to Board of Directors

Rexahn Pharmaceuticals, Inc. RNN, a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the appointment of Peter Brandt and Richard Kivel to the company's board of directors. “Peter and Richard are driving forces for innovation in the life science industry, and both are exceptional leaders who have accelerated corporate growth throughout their careers,” said Chang Ahn, Chief Executive Officer, Rexahn Pharmaceuticals. "Their proven expertise in commercializing biomedical innovations, and extensive financial and operational experience are significant assets to Rexahn as we continue to develop best in class CNS and cancer therapeutics and collaborate with pharmaceutical companies around the world.” "I am honored to join Rexahn's board. The company is at the forefront of developing innovative therapies for CNS disorders and cancer," said Mr. Brandt. "I look forward to contributing to Rexahn's evolution towards becoming a leading biopharmaceutical company." Mr. Kivel added, “This is an exciting time for Rexahn, particularly with three promising drugs in mid-stage development, and I look forward to helping the company capitalize on its impressive portfolio of potential new drugs.” Analyze Any Stock FREE! Click Here.